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Background: Artemisinin-based combination therapy (ACT) is the mainstay of global efforts for treatment of
Plasmodium falciparum malaria, but decline in its efficacy is the most important obstacle towards malaria control
and elimination. Therefore, the present molecular analysis provides information on putative mutations associated
with artemisinin resistance in P. falciparum clinical population unexposed and exposed to artesunate 4 years after
adoption of ACT as the first-line anti-malarial therapy in Iran.
Methods: In this study, blood samples (n = 226) were collected from uncomplicated P. falciparum-infected patients
from different health centers of Chabahar district in Sistan and Baluchistan province in the south-eastern part of
Iran, during 2003 to 2010. All collected isolates were analysed for putative candidate mutations (TTA) L263E (GAA),
(GAA) E431K (AAA), (GCA) A623E (GAA) and (AGT) S769N (AAT) of pfatpase6 gene using nested PCR/RFLP, followed
by sequencing. Furthermore, the gene copy number was assessed by real-time quantitative PCR (RT-qPCR) in the
presence of SYBR green.
Results: Neither the pfatpase6 L263E nor the A623E mutation was detected among all examined isolates. The
E431K mutation was found in 23% of the analysed samples unexposed to ACT; however, it was detected in
17.8% (34/191) of P. falciparum isolates exposed to artesunate after 2007. High frequency of this single nucleotide
polymorphisms (SNP) (overall 18.6%) among both examined groups (X2 test, P>0.05) indicated that this SNP should
be considered as an unrelated mutation to artemisinin resistance. In contrast, S769N mutation was not detected in
unexposed isolates; however, it was found in 2.6% (5/191), four years after introduction of ACT in this malaria
setting. Also, detected SNPs were not significantly frequent in both unexposed and exposed examined isolates
(X2 test, P> 0.05). Investigation in the copy number of pfatpase6 gene revealed a similar number of copy (n = 1) as
in an isolate sensitive to artemisinin.
Conclusion: Taken together, the results suggest, in particular, that pfatpase6 S769N gene needs more consideration
for its possible association with artesunate resistance among P. falciparum isolates.* Correspondence: zakeris@yahoo.com
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Plasmodium falciparum resistance is one of the most
important public health issues in many endemic countries
in the recent years. In the absence of a fully-protective
anti-malarial vaccine, malaria control heavily relies on
the use of drugs for treatment or prophylaxis. However,
the increasing failure of the predominantly used and safe
drugs, especially chloroquine (CQ) and sulphadoxine-
pyrimethamine (SP), has been a serious obstacle towards
global malaria control. Consequently, to overcome the re-
sistance problem, the World Health Organization (WHO)
and health authorities in malaria endemic countries rec-
ommend the use of a therapeutic combination. They rec-
ommend the use of artemisinin derivatives in combination
with other drugs (ACT) in order to provide a better effi-
cacy and avoidance of resistance nationwide [1,2]. As a
result, following increased CQ and SP resistance, artemisi-
nin and its derivatives gradually became the mainstay of
falciparum malaria therapy. Besides, previous experiences
with other anti-malarial drugs showed that resistance
appears after long-term use. Recent reports of the reduced
artemisinin sensitivity of P. falciparum parasites in known
foci in Cambodia and Thailand, and new suspected foci
in Myanmar and Vietnam may suggest a decline in ACT
efficacy [3-5]. Therefore, due to the essential role of ACT
in malaria control and elimination, it is crucial to have a
regular surveillance of resistance to determine whether
resistance to artemisinin has developed or not.
The molecular mechanisms involved in underlying re-
sistance to artemisinin derivatives are not clearly under-
stood and identification of molecular markers would
provide insight into these mechanisms. Also, up to the
present, artemisinin resistance has not been clinically
documented, but it has been reported that the suscepti-
bility of P. falciparum to artemisinin derivatives is declin-
ing in several parts of the world [6]. Laboratory studies
have shown that genetically stable and transmissible
artemisinin-resistant rodent malaria parasite could be
selected through prolonged exposure of drug-sensitive
lines to low and increasing levels of artemisinin [7].
Molecular markers are recommended as the earliest
technique to detect emerging drug resistance; therefore,
the identification and monitoring of genes and mutations,
which correlate with resistance to artemisinin and its
derivatives, are essential for the evaluation and monitor-
ing of ACT. Previous studies on P. falciparum have pro-
vided evidence that few genes have been associated with
artemisinin resistance and these genes are sarcoplasmic/
endoplasmic reticulum Ca2+-ATPase6 (pfatpase6) [8,9],
pfmdr1 [10-13] and P. falciparum multidrug resistance
protein 1 [14-18]. However, PfATP6 protein might be the
major target of artemisinin in P. falciparum, as the drug
completely inhibits the activity of this protein [8,9].
Moreover, recent studies performed with both eukaryoticmodels and field isolates have proposed that single nucleo-
tide polymorphisms (SNPs) in the pfatpase6 gene are
involved in altered in vitro sensitivity to artemisinin or its
derivatives [9,19,20]. Also, different studies have previously
shown that pfatpase6 contains a number of SNPs [21-23]
and four of them (L263E, E431K, A623E, and S769N)
have been reported to be associated with a considerable
increase in artemether IC50 [19]. It has been also found
that the pfatpase6 S769N mutation is strongly associated
with raised artemether IC50 in P. falciparum isolates from
French Guiana [19]. Besides, it has been suggested that
the mutation at L263E codon is involved in the inhibition
of PfSERCA by artemisinin [9,19] and allelic exchange
study showed reduced susceptibility to artemisinin in
parasites expressing the L263E allele [21]. The combin-
ation of two additional SNPs, E431K and A623E, was
identified in one clinical isolate from Senegal that showed
a considerable increase in artemether IC50 [19]. Moreover,
other polymorphisms have been identified in pfatpase6
gene: I89T in Thailand [24], H243Y in Central Africa [25]
and silent mutation T2694A in São Tomé and Principe
[26]. In 2008, Dahlström and co-workers [22], who stud-
ied P. falciparum isolates from East and West Africa,
identified 33 SNPs; three of which were found in a fre-
quency higher than 5% at codons E431K, N569K and
A630S.
In October 2007, Iran has switched its first-line treat-
ment policy for uncomplicated falciparum cases to the use
of ACT. Nowadays, there is no other anti-malarial drug to
replace the artemisinin derivatives; thus, an urgent global
priority is needed to prevent potentially emergence and
spread of artemisinin resistance. The main goal of the
present study was to examine the mutation(s) in the
atpase6 gene of P. falciparum isolates unexposed and
exposed to ACT prior and four years after the adoption of
ACT as the first-line anti-malarial drug in hypoendemic
malaria settings. In fact, this study attempted to determine
whether drug pressure imposed by continuous deploy-
ment of ACT causes a potential selection of mutation(s) in




Study area and sample collection
In this study, blood samples were collected from dif-
ferent health centers of Chabahar district in Sistan and
Baluchistan province in the south-eastern part of Iran.
In this area, malaria transmission is year-round with
two peaks: the first peak occurs during May to August
and the second peak mostly happens around October to
November and the majority of the cases are infected
with Plasmodium vivax. Blood samples (n = 226) were
collected from uncomplicated P. falciparum-infected
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2010. The inclusion criteria were the presence of fever
for the preceding 48 h (axillary temperature ≥ 37.5°C),
mono-infection with P. falciparum, no intake of anti-
malarial drugs for the preceding four weeks and no signs
of complications. One milliliter venous blood was col-
lected from P. falciparum-infected patients prior to treat-
ment based on the National Guideline for treating
malaria (CQ from 2003 to 2005, CQ-SP from 2005 to
2007 and SP-artesunate from 2007 onward). All blood
samples were collected in a tube containing EDTA,
stored at 4°C, and then transported to the main labora-
tory in Tehran. Furthermore, a written informed consent
was obtained from all patients (adults or parents/legal
guardians of children) who were participated in the study
and an ethics approval was obtained from the Ethical
Review Committee of Research of Institut Pasteur, Iran.
Isolation of parasite genomic DNA from laboratory clones
and field isolates of P. falciparum
Parasite DNA was extracted from 300 μL blood samples
of either continuous culture of K1 laboratory strains or
field isolates of P. falciparum using the commercially
available DNA purification kit (Promega, Madison, WI,
USA), and kept at −20°C until use. DNA of P. falciparum
was detected by nested-PCR amplification of the small
sub-unit ribosomal ribonucleic acid (18ssrRNA) genes as
described previously [27]. The DNA was resuspended in
a Tris-EDTA buffer (10 mM Tris–HCl, pH 8.0, 0.1 mM
EDTA) and kept at −20°C until use.
Nested PCR-RFLP and sequencing
The fragment of pfatpase6 gene was amplified by nested
PCR with oligonucleotide primers and the cycling condi-
tion has been demonstrated in Table 1. Briefly, amplifica-
tion was carried out in a final volume of 25 μL, including
1 μL nest1 PCR product as template, 250 nM primers,Table 1 PCR/RFLP profiles used for genotyping of the pfatpas
PCR Reaction




Nest-1A F: TTGGTAATAAAACTCCCGC 58 (2’) 948
R: TATTCCTCTTAGCACCACTCC
Nest-2A F: TCATCTACCGCTATTGTATG 60 (1’) 775
R: TCCTCTTAGCACCACTCC
Nest-1B F: AAGAAGGATAAATCACCAAG 55 (1’) 725
R: AAATACACGTATACCAGCC
Nest-2Ba F: TAACCATTCTAATTATACTACAGCgCAGG 60 (1’) 141
R: TGTGTTGATGTGGTATTTATTTTATTACCC
Nest-2Bb F: AGAACAtTTAGCTTTGCTTATAAAAAAcTAA 60 (1’) 164
R: ATATGGCATAATCTAATTGCTCTTCCTAC10 mM Tris–HCl (pH 8.3), 50 mM KCl, 2 mM MgCl2,
125 μM each of the four deoxynucleotide triphosphates
and 0.4 U Taq polymerase (Invitrogen, Carlsbad, CA,
USA). Secondary PCR products were digested by four
enzymes: ApoI (Fermentas, Vilnius, Lithuania), MBoII
(Fermentas, Vilnius, Lithuania), Cac81 (New England
Biolab, Beverly, MA, USA) and DdeI (Fermentas, Vilnius,
Lithuania) and were used to identify mutations at posi-
tions L263E, E431K, A623E, and S769N, respectively
(Table 1). Secondary PCR products and digestion frag-
ments were resolved by electrophoresis on a 1.5 and
1.5-3% agarose gel, respectively.
Based on PCR-RFLP results, 40 samples (n = 20, 2003–
2006; n = 20, 2007–2010) were selected for sequencing
analysis of the entire pfatpase6 gene. Therefore, 4032 bp
(nt = −66 to 3966 in GenBank, accession no. AB121053)
of pfatpase6 gene, including all reported artemisinin-
resistant SNPs, was amplified by using the oligonucleo-
tide primers and the cycling condition has been described
in Table 2. Each pair of primers was designed to overlap
70 to 100 bp to cover all sequencing region. The ampli-
fied fragments were gel purified using the QIAquick Gel
Extraction kit (Qiagen, Hilden, Germany) following the
manufacturer’s instructions. Direct sequencing of the
DNA fragments was performed in both directions for
each PCR product using the dideoxy chain termination
procedure (Chemistry V3.1, Applied Biosystems) and
also the 3730XL DNA analyzer (Applied Biosystems) by
MilleGen sequencing service (Labege, France). Nucleotide
and amino acid sequences were aligned and compared
with wild-type sequences (accession no. AB121053) using
CLUSTAL W.
Estimation of the copy numbers of pfatpase6 gene by
real-time PCR assay
The gene copy number was assessed by real-time quan-






- - - -
L263E Apo I L: 775 E: 633+142
E431K MBoII E: 299+241+117+69+49 K: 416+241+69+49
- - - -
A623E Cac8 I A: 114+27 E: 141
S769N DdeI S: 136+28 N: 164
Table 2 Sequences of oligonucleotide primers and cycling
conditions used for full-length pfatpase6 sequencing
Primer Sequence (50→30) Ann (min) Size (bp)
F1: ATTATATCTTTGTCATTCGTG 55 (1’) 840
R1: TTGTAAAGGTGTTTGAGTATC
F2: TCATCTACCGCTATTGTATG 60 (1’) 775
R2: TCCTCTTAGCACCACTCC
F3: AAGTGTTGAGACGTTAGGATG 55 (1’) 698
R3: TTGATGATTGTACAGGTGTTG
F4: TGGAGACAGTACCGAATTAGC 60 (1’) 814
R4: TCTTCCTACATATTTACGTGGTG
F5: ATTGTAAAGGTGCACCTGAG 60 (1’) 922
R5: TTACCTAGTGCTGTTGCTGG
F6: TAGTAATATAGGAGAAGTTGC 60 (1’) 578
R6: TGTATGTTTGTGTGTGTGC
F7: ATCCACCAGAACATGACG 60 (1’) 760
R7: TCTTGGTTCTTTGCTCTTC
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tide primers (F: TTGCTGCTATACCAGAAGGATTGC
and R:TGTTGTCATTTGATTTGTTGTAAGGG) were
manually designed (accession no. AB121053) and verified
by both Primer ExpressW Software for real-time PCR
(Version 3.0, Applied Biosystems™) and Gene Runner
(Version 3.05). Amplification was carried out in triplicate
using the default thermocycler program in a total volume
of 20 μl in a 48-well plate (Applied Biosystems™), containing
10 μl 1× SYBRWGreen PCR Master Mix (Applied Biosys-
tems, Warrington, UK), 0.75 μl of each of the sense and
anti-sense primers (10 μM), 5 μL genomic DNA (20
ng) and 3.5 μL water, with amplicon size of 179 bp.
The program was: pre-incubation at 95°C for 10 mins,
followed by 40 cycles at 95°C for 15 seconds and at 60°C
for 1 min. A PCR negative control with no template was
used to check the presence of the dimmers and finally an
electrophoresis was used once at the end of the first
optimization plate to confirm that a single product of the
target gene is present. In this study, the 2−ΔΔCtmethod
for relative quantification was used to estimate the
copy numbers of pfatpase6 gene. In this method, to
estimate gene copy numbers in unknown samples, at
least one calibrator consisting of template DNA with
known copies of pfatpase6 (P. falciparum K1 with one
copy of atpase6) and a house-keeping gene of constant
copy number in all samples (pf-β-tubulin gene) are
required. The formula for the estimation of gene copy
numbers in clinical isolates of P. falciparum is as followed:
ΔΔCt = (Ct target gene - Ct pf-β-tubulin)unknown sample -
(Ct target gene - Ct pf- β-tubulin) K1. Then, the result for
each sample was expressed in N-fold changes in unknown
samples (2−ΔΔCt). A minimum of two experiments was
carried out for each sample and the results were expressed
as the N-fold copy number of a given gene relative toP. falciparum K1, by calculating the mean between
the two experiments. In the case where N-fold was be-
tween 0.5 and 1.6 (0.5 < N-fold < 1.6), it was accepted
that the test sample harbored a single copy of the target
gene.
In the present study, β-tubulin as a house-keeping
gene was amplified using the primers described previ-
ously [28]; F: TCGTCAACTTCCTTTGTGGA and R:
TCCCATTCCCACGTTTACAT). To normalize quanti-
tative data in each reaction, all samples were analyzed in
triplicate within each LightCycler run and the average
value was accepted if the standard deviation was lower
than 0.24. The genomic DNA samples used were the
same as those used for gene amplification and sequen-
cing. The purity and quantity of DNA were determined
by UV spectrophotometry. To determine RT-qPCR effi-
ciencies, standards consisting of 2-fold serial dilutions of
genomic DNA were freshly prepared from concentrated
stocks for each experiment. Genomic DNAs in the range
of 64 to 1 ng were used as quantification standards for
the LightCycler calibration curve. Then, amplifications
were performed on the same diluted samples using pri-
mers for the reference (pf-β-tubulin) and the target genes.
The average Ct was calculated for both reference and tar-
get genes, the ΔCt (Ct target gene - Ct pf-β-tubulin) was
determined and the log DNA dilution versus ΔCt was
plotted. The efficiency of the PCR should be 90-100%
(-3.6 > slope > -3.1). If the absolute value of the slope
was close to zero (0.1), the efficiencies of the target and
reference genes were similar, and thus the ΔΔCt calcula-
tion could be applied.
Statistics
All statistical analyses were performed using SPSS stat-
istical package (version 16.0). Frequencies of muta-
tions and haplotypes among the groups were compared
using the X2 test. P<0.05 was considered statistically
significant.Results
Sample characteristics
In this investigation, pfatpase6 gene was successfully
amplified in all field samples (n = 226). Of 226 P. falcip-
arum isolates, 35 samples were collected before the
adoption of ACT as the first-line anti-malarial drug in
Iran during 2003–2006 with no artemisinin pressure.
Also, 49 of 226 samples were collected in 2007, when
the artemisinin pressure was very low. Although SP-
artesunate was selected to replace CQ-SP in the study
areas in year 2007 all malaria settings in Iran undoubt-
edly used SP-artesunate as the first-line therapy in 2008.
Other 142 of 226 samples were collected after the full
adoption of SP-artesunate in Iran.
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All 226 P. falciparum samples were successfully geno-
typed. Surveillance of pfatpase6 SNPs within positions
L263E, E431K, A623E, and S769N indicated no (0/226),
18.6% (42/226), no (0/226), and 2.2% (5/226) prevalence
of pfatpase6, respectively (Table 3). The majority of the
patients (80%, 181/226) was found to carry wild type
while single mutant haplotype (L263K431A623S769), as
the second predominant allele, was detected in 16.4%
(37/226) studied isolates (Table 3).
According to the year of sample collection, before
2007, the prevalent haplotypes were wild type (77%) and
L263K431A623S769 (23%); however, the most frequent
haplotype in 2007-2010 was wild type (80.6%) (Table 3).
In addition, the number of haplotypes increased from
2 to 6 after ACT adoption in Iran (Table 3). Before and
after the introduction of ACT, the prevalence of pfat-
pase6 E431K mutation in Sistan and Baluchistan prov-
ince was 23% (8/35) and 17.8%, (34/191) respectively
(Table 3). However, S769N mutation was not detected in
any unexposed isolates, but found in 2.6% (5/191) of the
exposed isolates (Table 3).Sequencing the full length of pfatpase6 gene
The pfatpase6 gene of 4032 bp in length was successfully
sequenced from the PCR products of 4060 bp by using
7 overlapping paired primers. Both non-synonymous
and synonymous mutations were detected at different
frequencies in comparison with the reference sequence
(accession no. AB121053) as shown in Table 4. Sequen-
cing analysis of samples confirmed the RFLP results. In
addition, nine different non-synonyumous mutations at
codons 89 (87.5%), 230 (%2.5), 355 (15%), 431 (57.5%),
569 (87.5%), 630 (100%), 683 (97.5%), 769 (6.5%) and
870 (2.5%) were detected in high frequency among both
unexposed and exposed P. falciparum isolates (X2 test,
P>0.05) (Table 4).Table 3 Frequency distribution of putative SNPs and haploty
unexposed (<2007) and exposed (>2007) to ACT
Gene pfatpase6
Haplotype L263E E431K A623E S769N
LEAS L E A S
LKAS L K A S
LEA(SN) L E A SN
L(EK)AS L EK A S
LKA(SN) L K A SN
L(EK)A(SN) L EK A SN
* Unexposed P. falciparum isolates to ACT.
** Exposed to ACT with high pressure.
*** Exposed to ACT introduction of ACT as first-line anti-malarial therapy for 4 yearsCopy number of pfatpase6 gene
In this study, to obtain optimal efficiency, RT-qPCRs
were first optimized for each gene by both PCR reagent
concentrations and primers and for each gene (including
target, house-keeping and reference genes), PCR efficien-
cies were obtained for about 95% of all cases (data not
shown). Regarding the further validity of the RT-qPCR
assay, the copy number of pfatpase6 gene was compared
with the laboratory clone P. falciparum K1 with only one
copy number for the mentioned gene. After finding the
optimal conditions for pfatpase6 gene, the estimated
gene copy number of all examined field isolates was 1.0
equal to the reference isolate K1.
Discussion
ACT is the mainstay of global efforts to control P.
falciparum malaria, but suspected failure of artemisinin
is the most important obstacle towards malaria control
and elimination [5]. At the present, no alternative classes
of anti-malarial drugs are available to replace the artemi-
sinin derivatives; hence, an urgent global priority is
needed to prevent potentially the emergence and spread
of artemisinin resistance. To achieve this goal, deter-
mining the molecular mechanism of artemisinin and its
derivative resistance is very important. Therefore, the
present molecular analysis provides, for the first time,
baseline information on putative mutations (L263E,
E431K, A623E and S769N) associated with artemisinin
resistance in P. falciparum population unexposed and
exposed to ACT in low endemic areas of Iran. In this
study, by using nested PCR-RFLP followed by sequencing
analysis, neither pfatpase6 L263E nor A623E mutations
was detected among P. falciparum isolates unexposed
(before 2007) and exposed (after 2007) to ACT. In
addition, L263E mutation was never found in field iso-
lates [3,19,20,22,23,26,29-33], similar to the present find-
ing, and its association with artemisinin resistance needs
more studies to be confirmed.pes of pfatpase6 gene in 226 P. falciparum isolates
Year Total
<2007* 2007** 2008-2010*** n=226 (%)
n=35 (%) n=49 (%) n=142 (%)
27 (77) 44 (89.8) 110 (77.5) 181 (80)
8 (23) 4 (8.2) 25 (17.6) 37 (16.4)
- 1 (2) 2 (1.4) 3 (1.3)
- - 3 (2.1) 3 (1.3)
- - 1 (0.7) 1 (0.5)
- - 1 (0.7) 1 (0.5)
.
Table 4 Sequence analysis of SNPs in full-length
pfatpase6 among 40 P. falciparum clinical isolates
unexposed (n = 20) and exposed (n = 20) to ACT
A: Nonsynonymous
Position ≤2007 >2007
nt aa Codon n=20 n=20
266 89 T AcA 0.25 0
I AtA 0.75 1
689 230 I AtC 0.95 1
T AcC 0.05 0
1063 355 I aTA 1 0.7
L tTA 0 0.3
1291 431 E gAA 0.45 0.40
K aAA 0.55 0.60
1707 569 K AAa 0.25 0
N AAt 0.75 1
1888 630 T aCT 0 0
H gCT 0.95 1
S tCT 0.05 0
2049 683 K AAa 0 0.05
N AAt 1 0.95
2306 769 S AgT 1 0.87
N AaT 0 0.13
2610 870 F TTt 1 0.95
L TTa 0 0.05
B: Syonymous
981 327 A GCa 0.05 0
A GCt 0.95 1
1449 483 N AAc 0.2 0
N AAt 0.8 1
2694 898 I Ata 0.8 0.95
I ATt 0.2 0.05
2703 901 V GTa 0.95 1
V GTt 0.05 0
3090 1030 K AAa 0.05 0.05
K AAg 0.95 0.95
3093 1031 C TGc 0.95 1
C TGt 0.05 0
3309 1103 Y Tat 0.95 1
Y TAc 0.05 0
nt: nucleotide.
aa: amino acid.
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SNP in the collected samples before 2007; however,
17.8% were detected in P. falciparum samples exposed
to artesunate after 2007. The pfatpase6 E431K mutation
has been suggested to be associated with increased arte-
sunate IC50 in Senegal [19] and this SNP has also been
reported from African, Asian and South American P.
falciparum isolates. In the present findings we found ahigh frequency of this SNP among P. falciparum popu-
lation unexposed and exposed to artesunate, indicating
that this SNP is unlikely associated with artemisinin re-
sistance. Furthermore, the most prevalent haplotype
was wild type with a frequency of 77% before 2007 and
80.6% after 2007. The second most frequent haplotype
was L263K431A623S769 with 23% and 15.2% frequency be-
fore and after ACT adoption in Iran, respectively. In a
previous in vitro study, this haplotype with single muta-
tion was sensitive to dihydroartemisinin [33] and the
results suggested that the high frequency of E431K
among Cameroonian P. falciparum isolates might be a
warning signal for artemisinin drug resistance. Also, al-
though this mutation in high frequency (overall 18.6%)
was found among Iranian P. falciparum isolates, the
non-significant prevalence (X2 test, P>0.05) among para-
site population unexposed and exposed to ACT sug-
gested that this mutation might have not been selected
under artemisinin pressure.
Pfatpase6 S769N mutation has been reported to affect
the PfSERCA activity with increased artemether IC50
and it was originally found in P. falciparum field isolates
from French Guiana [19]. However, it was not reported
from China [34], Tanzania [32], Niger [31] and Brazil
[35] with a different level of malaria endemicity. In
parallel, this mutation was not detected in 35 Iranian
P. falciparum isolates collected during 2001-2002 when
CQ was used as first-line anti-malarial therapy [36]. In
addition, in the present investigation, further analysis on
P. falciparum isolates collected during 2003-2006 (when
CQ-SP was used as the first-line treatment) revealed no
S769N mutation. Since ACT was used as the first-line
treatment for uncomplicated falciparum malaria in Iran
(in 2007), the frequency of this mutation has started to
increase (2.6%). Detection of this mutation in only para-
site isolates exposed to artesunate might suggest the
likely selection of this mutation by artemisinin pressure
as the previous study suggested the pfatpase6 S769N mu-
tation as a potential molecular marker for P. falciparum
resistance to artemether [19]. Also, the most frequent
haplotype before and after ACT adoption was wild type,
but the number of haplotypes increased from 2 to 6 in
parasite isolates unexposed and exposed to ACT, respect-
ively (Notably, parasites carrying pfatpase6 S769N muta-
tion). Nonetheless, recent report by Cui et al. [37], using
allele exchange strategy revealed that 3D7 parasite carry-
ing 769N mutation was still sensitive to artemisinin and
its derivatives. This evaluation was done by in vitro re-
sponse of transgenic lines to aforementioned drugs [37].
Although this result argue against the predicted role of
pfatpase 769N in resistance to artemisinin and its deriva-
tives, but many variables including genetic backgrounds
of the parasites may significantly influence on parasite re-
sistance to various anti-malarial drugs [38-42]. Therefore,
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[19, 37, present study] the role of this candidate mutation
in artemisinin and its derivative resistance needs further
study.
In conclusion, the pfatpase6 genotype and its copy
number might make early warning signals for the emer-
gence of ACT resistance and provide baseline data for
anti-malarial drug policy. Until now, there is no evidence
for assuming that artemisinin resistance has occurred in
Iran (Iranian Center for Disease Management and Con-
trol, surveillance report, unpublished). Therefore, the
present results suggest that, to confirm and distinguish a
mutation associated with artemisinin resistance, more
studies are required among P. falciparum population
unexposed and exposed to ACT from global malaria
endemic setting. However, the pfatpase6 S769N mutation
needs more awareness for its association with artesunate
resistance and its value as a molecular marker for moni-
toring artemisinin resistance among P. falciparum popu-
lation remains to be validated in areas where ACT has
been used for a longer period. Introducing such a mo-
lecular tool could support the national and global malaria
control and elimination programmes.
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